PoCMICRUX

Longer life expectancies and unhealthy lifestyle has dramatically increase the prevalence multiple chronic conditions. There are over 50 million of people with such cumulative chronic conditions in Europe and, together, they total more than €700 billion healthcare expenditure which account for over 70% of the EU health budget. Recent Point-of-Care Testing (PoCT) technologies provide remarkable tools for home self-testing and management but the currently PoC on the market are still so complex and too expensive to be afforded by average patients. With PoCMicruX we intend to overcome this barrier and finally provide patients the first low-cost multi-analyte handheld Point-of-Care device for multiple chronic disease self-testing and management. PoCMicruX is a combination of microfluidic and electrochemical sensor technologies. Based on an innovative design totally made of electronical components and where fluid can simply be handled by capillary action, we will offer the only cost-effective (€150), simple (one drop of blood, no training or calibration required), fast (<2 min), and handheld PoC device allowing patients to accurately self-test simultaneously four clinical validated biomarkers (glucose, cholesterol, creatinine and uric acid) for the clinical diagnostic (monitoring and prevention) of high prevalence diseases such as diabetes, cholesterol, cardiovascular and kidney diseases. MicruX Technologies is a highly innovative Spanish company that, from its foundation in 2008, has been at the forefront of developing miniaturized lab-on-chip technology and miniaturized monitoring instrumentation, being already involved in several EU projects. We have already succeeded in launching more than 30 models of products currently marketed in 40 countries. We expect from PoCMicruX commercialization to provide an accumulated turnover of €26.7 million by 2023, with 8.5 million profit (profitability ratio of 57%). We foresee to create 50 new jobs by 2023.